Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Enzalutamide for Castration-resistant Prostate Cancer

Jul 16, 2018, 11:06 AM
URL:

On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC).

This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Enzalutamide was previously approved for the treatment of patients with metastatic CRPC.

Read FDA announcement.

Posted 7/16/2018

Leave a comment